lobbying_activities: 2597157

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2597157	909fc0f9-87cd-4873-8016-70be99794c19	Q1	ASSOCIATION FOR ACCESSIBLE MEDICINES	16032	ASSOCIATION FOR ACCESSIBLE MEDICINES	2021	first_quarter	PHA	Prescription Drug Costs. Drug Pricing. Pharmaceutical Exclusivity. 180-Day Exclusivity. Forfeiture of 180-Day Exclusivity. 12-Year Exclusivity. Contract Genericization. 30-Month Stays. Labeling of Generic Drugs and Biosimilars. Modern Labeling. Generic carveouts patent protected information in drug labels, including issues related to GSK v. Teva. Orange Book. Drug Shortages. S.917: Short on Competition Act. Stockpile of Generic Drugs. Generic Drug User Fee Amendments (GDUFA). GDUFA III Negotiations. Biosimilar User Fee Act (BsUFA). BsUFA III Negotiations. Biosimilars Naming. Biosimilars Insulin. Pass-through Payments for Biosimilars. Cost Sharing for Biosimilars. Implementation of Food and Drug Administration Reauthorization Act (FDARA). FDA Inspections. Buy American Proposals. Issues Related to COVID-19. Secretary Azar Importation Plan.	Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,U.S. Trade Representative (USTR)		880000	0	0	2021-04-16T10:45:32.463000-04:00